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ABSTRACT 
TITLE- -Study of autonomic dysfunction in patients with  Guillain- 
 
             Barré syndrome (GBS) 
 
DEPARTMENT-NEUROLOGY, CMC VELLORE 
NAME OF THE GUIDE -DR.MATHEW ALEXANDER 
INTRODUCTION- Guillain Barre syndrome is an immune mediated inflammatory 
disease of the PNS characterized by rapidly evolving symmetrical limb weakness, loss of 
tendon reflexes and absent or mild sensory signs .Autonomic neuropathy is an important and 
common complication of Guillain-Barré syndrome (GBS)  and may be life threatening at 
time.The available studies showed variable incidence  of autonomic dysfunction in GBS and 
its relation with  the severity of motor paralysis and sensory disturbances. 
 OBJECTIVES- To study autonomic nervous system involvement in a group of patients’ 
with  Guillain- Barré syndrome (GBS) to assess  its clinical significance  and  relation with  
clinical severity of GBS and its subtypes. 
METHODOLOGY: Continuous recording of HR and BP and longitudinally performed 
autonomic function tests’, including HR response to deep breathing and standing,valsalva 
ratio,postural change of systolic BP and cold immersion test were done once daily for the first 
3 days of admission followed by once every week . The recordings’ were continued till the  
4th week of illness or improvement by 1 functional grade (Hughe’s Grading), whichever was 
earlier.  
RESULTS:  8 patients (7AIDP/IAMAN) were included for longitudinally performed 
autonomic function tests’ (ATs). Autonomic dysfunction were detected  in 7/8 patients  
  
(87.5%) including one AMAN. Two patients (25%) had dysautonomia of severe grade with 
NTAS >16.  Symptoms of dysautonomia  were  reported in  6/8 patients (75%)  of  which it 
was started  1-5 days before the onset  of motor weakness in 3 patients. The most frequent 
manifestation of dysautonomia  in our patients was sinus tachycardia  (87.5%) followed by 
Hypertension,labile HR and labile BP(75 % each).Episodes of hypotension was reported in 
50% patients where as bradycardia in 37.5% patients. HR response to deep breathing (I-E 
differences) was abnormal in 3/ 6 patients (50%), where as HR response to active standing 
(30:15 ratio) 1/2 patients who was able to perform the  test . Valsalva ratio was abnormal in 
one of 2 patients (50%). 62.5% of  patient fails to rise of diastolic BP significantly in Cold 
immersion test where as 50 %  patients who was able to stand unsupported  was showing 
significant fall of systolic BP on standing at or before 3 min. SSR was absent in  62.5% 
patients (4 AIDP /1AMAN ) in both upper and lower limbs. All patients in whom SSR was 
absent , had evidence of dysautonomia.  
CONCLUSION:The   present study demonstrated high incidence of autonomic     
dysfunction in patient with GBS (87.5%). Fifty percent patients had evidence of both 
sympathetic and parasympathetic dysfunction ,25 % patients predominantly sympathetic 
dysfunction where as 12.5% patients  had  predominantly parasympathetic dysfunction.The  
presence and severity of dysautonomia(NTAS) was not related to motor disability ,sensory 
disturbances and use of mechanical ventilation but was correlated with older age (>45 yrs) of 
onset of illness.  
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INTRODUCTION 
Guillain Barre Syndrome is an immune mediated  inflammatory disease of the peripheral 
nervous system characterized by rapidly evolving symmetrical limb weakness, loss of 
tendon reflexes, absent or mild sensory signs and variable degree of autonomic 
dysfunction and cranial nerve involvement. The clinical spectrum consists of four major 
subgroups - Acute inflammatory demyelinating  polyradiculo neuropathy (AIDP), Acute 
motor axonal neuropathy (AMAN), Acute motor sensory axonal neuropathy (AMSAN) 
and Miller–Fisher syndrome.Autonomic neuropathy is an important and common 
complication of Guillain-Barré syndrome (GBS) and occurred in approximately two-third 
of patients 1,2.Most of the previous studies of autonomic dysfunction in GBS are those 
with  AIDP, except a study from China comparing autonomic dysfunction between 
AMAN and AIDP3 and from Taiwan,  who studied cardiovascular autonomic dysfunction 
in nine of  Miller Fisher syndrome4.These small studies  had shown different patterns and 
severity of dysautonomia in GBS and its variants’, probably due to difference in 
immunopathogenesis and target molecules. A wide range of  symptoms have been 
described  including arrhythmias of various type, abnormal fluctuation of blood pressure 
and heart rate, gastrointestinal and genitourinary dysfunction ,sweating abnormalities 
,abnormal hemodynamic response to drug and tracheal  suction.Signs of Sympathathetic 
and Para sympathetic failure may be present as well as over activity of sympathetic and 
parasympathetic nervous system. Both features may be present even in the same patient. 
The lesion may occur in the afferent arterial baroreceptors,sympathetic efferent’s to  
arterioles and veins or in the efferent cardiac parasympathetic innervations carried in the 
vague nerve5.Some patients with Guillain-Barré syndrome have severe autonomic 
dysfunction that can be life threatening and may require the placement of  a cardiac 
pacemaker. Serious arrhythmias was thought to occur in severely disabled patient, mainly 
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in those who needed mechanical ventilation6 ,recent study indicate that these life 
threatening complication may  also developed in less severely affected patient even in 
those who were still able to walk more than 5 meters. Majority of the available studies 
showed no correlation  between degree of dysautonomia and severity of motor paralysis, 
sensory symptoms and motor nerve conduction velocities7Available studies indicated that  
dysautonomia recovered with recovery of motor paralysis.Most of the available studies on 
autonomic dysfunction in GBS were done on limited number of patients, mainly 
AIDP.Inspite of emergence of PE and IVIg as a treatment option in  GBS during last 
three decades’, that halts the progression of disease and shortens’ the duration of illness 
but fatality of GBS remains unchanged 8,9 which is mainly due to dysautonomia.Since 
dysautonomia is an   important factor responsible for fatalities in this disease,patients with 
dysautonomia  should be monitored closely until  they recovered from it. The pattern and 
prognosis of autonomic dysfunction in GBS require more number of studies on larger 
number of patient,s including axonal variants of GBS, which would help to understand 
this much better and utilize this  in clinical practice, to pre-empt, detect and treat life 
threatening dysautonomia and thereby avoid fatality. 
Epidemiology of GBS: GBS is the most common cause of post infectious 
neuromuscular weakness world wide .The incidence rate varies between 0.6-4 cases per 
100,000 population 10,11 the lifetime likely hood for an individual developing GBS is 
approximately 1:1000 12 The GBS  can occur at any age with attack rate’s being higher in 
persons’ between 50-74 yrs of age 13 but in china  the incidence rate is about the same in 
child hood and much less in adult than in adult elsewhere. Most cases are sporadic ,but small 
cluster have been associated with outbreak of bacterial enteritis caused by contaminated 
water 14 and summer epidemics in northern china ,probably due to infection with 
Campylobacter jejuni 15 
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Antecedent Events  in GBS:About 2/3rd of GBS patients report  a preceding 
event 1-4 weeks prior to onset of neurological symptoms.  Prior infection is well established 
as a precipitating event in the development of GBS. Most antecedent illnesses associated with 
GBS affect the upper respiratory tract, followed by GI tracts.   
Antecedent Events                              Percentage   
Respiratory  illness                                                                      58% 
Gastrointestinal illness                                                                  22% 
Respiratory  illness and Gastrointestinal illness                           10% 
Surgery                                                                                        5% 
Vaccination                                                                                  3% 
Others                                                                                          2%      
16(Govoni and Granieri  -2001) 
The specific infectious agent related to GBS includes:C.Jejuni,Mycoplasma 
Pneumoniae,CMV,Varicella Zoster,EBV ,HIV,Hepatitis A and Hepatitis B. 
The preceding infection detected serologically in 2 large series with GBS are 
Netherland (n=476)        North America  and Europe(n=383) 
1987-96                                                           1993-1995 
 
C.Jejuni                               32                               23 
 
Cytomegalo  Virus             18                                  8 
 
Epstein Barr Virus             7                                    2 
 
Mycoplasma Pneumoniae  9                              Not tested 
 
Campylobacter jejune is the most common identifiable organism linked to GBS 
particularly , the  axonal form.The  evidence of C.jejuni  infection from  Stool culture and 
serological tests’ in patient’ admitted with GBS varies in different parts of the world, 
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specially having in northern China where infection rate of 76% was seen in patients with 
AMAN and 42% in patient with AIDP were found 17 The C. jejune  is a gram negative rod is 
common cause of bacterial enteritis world wide .It is characterized by watery /bloody 
diarrhoea and abdominal cramping.   
Study have shown  that the lipopolysaccharides of these  organisms share ganglioside like 
epitopes  with peripheral nerves .18 This molecular mimicry appears to confuse the immune 
system, resulting in mistaken attack against  neural antigens. The development of GBS only 
in certain percentage of  C.Jejuni infected patient is  probably related to host factor or certain  
Polymorphism of C.jejuni.19 
.Clinical features of GBS:Typical GBS is an acute, predominantly motor neuropathy 
presenting as  distal limb paresthesias, relatively symmetric limbs weakness, and frequent 
gait ataxia. Fever or other constitutional symptoms are absent at the onset of illness.The usual 
pattern is an ascending paralysis evolving over hours to few days. Proximal muscle weakness 
occurs very frequently, especially initially, with subsequent distal arm and leg weakness.  In 
about 15%  cases  of GBS, a descending pattern of weakness is seen 20 .Usually, symmetric 
distal limb paresthesias develops ( in about 50 % cases of GBS) before clinically evident limb 
weakness.Sensory loss is not an important features of GBS and frequently limited to distal 
impairment of vibration sense. Pain of moderate to severe grade occur in about 2/3rd of GBS 
patient mainly at the onset of illness.21Reduced or absent deep tendon reflexes are seen at the 
onset or within first few days of onset of symptoms.The  early loss of reflexes may be due to 
desynchronization of afferent impulses in reflex arc due to non-uniform 
demyelination.Involvement of  Cranial nerves’ are  seen 45%-75% cases of GBS in different 
series. 22 Facial paresis  usually bilateral is found in at least 50% cases of GBS.The proportion 
of patients developing respiratory failure  following diaphragmatic or Respiratory muscles 
involvement  and requiring assisted ventilation  varies between 13%-30 % in different 
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 Series .23Dysautonomia is  common and may occur even in milder form of  GBS. Usual 
features are loss of vasomotor control with wide fluctuation in blood pressure, postural 
hypotension, and cardiac dysrrhythmias  and can be life threatening and required close 
monitoring and management. 24There may be postural dizziness,palpitation, increased 
thirst,bladder and bowel dysfunction and sweating abnormalities. 
Variants of GBS: Depending upon topography,Clinical course ,types of fiber 
involved  and Pathological features patient  of GBS can be classified into following sub type     
1) Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) 
2) Acute Motor Axonal Neuropathy (AMAN) 
 
  3) Acute Motor and Sensory Axonal Neuropathy (AMSAN) 
 
4) Miller-Fisher syndrome 
 
5)  Pan dysautonomia  
 
6)  sensory GBS 
 
7) Polyneuritis cranialis 
Course and prognosis of GBS:The  disease reaches its nadir by 2   weeks in most 
cases and in 4 weeks in nearly all patients’. After progression stops, patients’ enter a plateau  
phase lasting for 2-4 weeks, and recovery begins with return of proximal followed by distal 
strength over weeks or months 25. According  to studies,72 % of patient have complete 
recovery in  1 year  and 82% in 2 years time. 26The most common residual difficulties are 
weakness of the lower leg muscles, numbness of the feet and toes, and mild bifacial 
weakness. A few patients are left with a sensory ataxia, which may be disabling Distal 
neuropathic pain and persistent autonomic problems occur but are infrequent. The mortality 
rate varies between 2-7% of patient  in different series.27,28.In the early stages, death is most 
often due to cardiac arrest. perhaps related to dysautonomia and later in the illness, 
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pulmonary embolism and infectious  complications  of prolonged immobilization and 
respiratory failure are the main causes.In several studies ,preceding diarrhoeal illness,  
C.jejuni infection had more severe disease and a delayed recovery  when compared with 
other patients’29 
Pathogenesis of GBS:   The clinical and experimental evidence suggest that GBS is an   
organ specific  immune mediated disorder  caused by interaction of cell mediated and 
humoral  immune response  to peripheral nerve antigen 30,31.A  preceding infection may 
trigger an auto immune response through  molecular mimicry.The infectious agents have 
epitopes on their surface that are similar to epitopes on the surface of peripheral nerves (e.g., 
gangliosides, glycolipids,resulting in the peripheral nerve acting as a ‘‘molecular mimic’’ of 
the infectious agent. 32 As carbohydrate moieties of gangliosides (e.g., GM1, GD1a, GQ1b) 
found on the  surface of the peripheral nerve are structural  mimics of  the  lipo 
oligosaccharides (LOSs) of C. jejune.33 Initially activated T cells play a major role in the 
opening of blood nerve barrier  and allow circulating antibody to gain access to peripheral 
nerve antigen.The activation marker of T cells (IL-6,IL-2,Soluble IL-2 receptor  and INF Y) 
and  pro inflammatory cytokines released by  T cells and macrophages ,TNF alpha are 
increased in patient serum.Soluble E selecting, adhesion molecules and matrix 
metalloproteinase’s are increased  in early stage of patients with GBS and are involved in 
facilitating  recruitment and transmigration of activated T cells and monocytes through the 
blood nerve barrier.A cell mediated  immune response against the myelin  component is 
supported by Experimental autoimmune Neuritis, the accepted animal model for  AIDP. 
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Experimental autoimmune  neuritis:The pathology  of AIDP closely 
resembles that of experimental autoimmune neuritis induced in animal by   active 
immunization with whole peripheral nerve homogenate, myelin or PNS specific myelin basic 
protein P2,P0,P22  or galactocerebroside. 34 Study  indicate that humoral factors also having 
significant role in the pathogenesis of GBS and participate in the autoimmune attack on 
peripheral nerve myelin,axon and nerve terminals as 35 
a) Immunostaining shows deposition of immunoglobulin and complement on the  
 
   myelinated fiber of affected patient. 
 
b) AMAN and MFS are associated with specific type of anti ganglioside antibody 
 
c)AMAN and MFS  patient’s sera contain Gig antibodies that block neuromuscular  
  
    transmission in a mouse nerve-muscle preparation. 
 
d)Injection of GBS serum intraneurally  into rat sciatic nerve results in secondary T-cells  
 
    infiltration of injection site at the time of hind limb weakness. 
 
e) Complement C1-fixing anti peripheral nerve myelin antibody can be detected in the sera  
 
     of patient in acute stage of GBS. 
 
f)Clinical recovery after plasma exchanges or IVIg has suggested that humoral factors play a  
 
    prominent role.    
 
Pathogenesis of AIDP:The immune attack in AIDP appears to begins  with binding of 
auto antibodies to specific epitopes on cell schwann membrane with with consequent 
activation of complement.The nature of epitope in AIDP is likely to be a glycolipid.The 
complement activation product with membrane attack complex  are seen on the outermost 
schwann cell surface within days of onset of symptoms ,leads to vascular myelin changes 
followed by recruitment of macrophages and progressive demyelination.In severe cases 
secondary axonal degeneration occur probably secondary or by-stander consequence of 
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enzymes or radicals released by immune mediated inflammatory response directed against  
the myelin.  
AMAN:Acute  motor axonal neuropathy  is caused  by an  antibody and complement 
mediated attack on axolemmal epitopes of motor fibres.The target epitopes are GM1 and 
asialo GM1-like gangliosides,which are present in the nodal intermodal membrane of motor 
fibers.36 In AMAN, following   deposition of activated complement component and immune 
globulins at the nodal axolemma, leads to disruption of par anodal  space and entry of 
complement and immunoglobulin’s along the  axolemma with subsequent recruitment of 
macrophages to affected nodes. These macrophages are shown to invade the peril axonal 
space ,leading to axonal degeneration.37 AMAN, antibody binding may alter sodium channel 
function leading to conduction  block. The reversal of Gig -mediated conduction block before 
development of axonal degeneration may explain the relatively  rapid improvement of  many 
of acute axonal neuropathy cases. 
AMSAN:The  pathology of AMSAN resembles AMAN but in AMSAN both ventral and 
dorsal root are affected.There is similar pattern of paucity of lymphocytic inflammation 
consistent with  antibody mediated pathogenesis. 
Miller Fisher Syndrome:Pathophysiological  features of  Miller Fisher Syndrome 
shares many aspects  with AIDP and Acute motor axonal neuropathy.Molecular mimicry 
between infection (e.g., C. jejuni)and surface components of peripheral nerve plays a key role 
leading to humoral and complement activation with MAC formation and nerve axon terminal 
damage.38 The main  difference between MFS and AIDP or Acute motor axonal neuropathy 
is the activation of anti-GQ1b and anti-GT1a antibodies in MFS that target occulomotor and 
bulbar nerves, which are nerves thought to have relatively high GQ1b and GT1a ganglioside 
densities.39 The pre synaptic nerve  terminal axons and peril synaptic Schwann cells are 
damaged in MFS. 
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Antibodies associated with GBS and its variants 40 
1) AIDP                                                             unknown                 
2) AMAN                                                       GM1,GM1b,     GalNac-GD1a                                                                               
3) AMSAN                                                          GM1,GM1b,GD1a                                                                                                                 
4) Miller-Fisher syndrome                                   GQ1b,GT1a 
5)  Pan Dysautonomia 
6)  Sensory GBS                                                  GD1b  
7) Polyneuritis cranialis                                     GT1a 
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      AIMS AND OBJECTIVES  OF STUDY .  
 
1) To study autonomic nervous system involvement in a group of patient of   
       Guillain- Barré syndrome (GBS)  
2) To assess the clinical significance of the autonomic nervous system  
         involvement in such patients. 
     3) To assess  the relation  of autonomic dysfunction  with clinical severity of  
          GBS  
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REVIEW OF LITERATURE 
Autonomic  neuropathy  is an  important  and common  complication of Guillain-Barre  
syndrome  (GBS).The neuropathy may  involve visceral afferent  fibers  sub serving  the  
autonomic  nervous  system  (ANS), parasympathetic efferent fibers, sympathetic efferent’s, 
or a combination of these territories. Manifestations may  be present in  Cardiovascular, 
Genitourinary, Gastrointestinal,Sudomotor and other systems involving both sympathetic  
and  parasympathetic  fibers to a  different degree. There are a few studies’ in literature,  with 
variable examination of  the autonomic nervous  system. The literature suggests that the 
incidence of autonomic disease in GBS varies directly with  the intensity  of  the  search.41 . 
Experimental models of autonomic neuropathy in GBS 
The most accepted model  of  GBS is experimental allergic  neuritis  (EAN),having evidence 
of involvement of autonomic nervous system mainly of myelinated structures of both 
sympathetic and parasympathetic arms.Waksman and Adams, who originally described EAN 
in rabbits reported lesions at the origin of the sympathetic white ramie communicans with 
preservation of sympathetic ganglia 42. Tuck et  al later provided  evidence that  autonomic 
myelinated  fibers were  targets of EAN  in  the  guinea  pig 43.  Tuck observed fall in 
amplitude of the vague and  splanchnic  nerve compound action potential, temporal  
dispersion and a reduction  in  conduction velocity and on histological  evaluation  
demonstrated  evidence of demyelination in 25% of the vague nerves studied  and 56% of  
the splanchnic nerves.  In addition there was reduction of density  of  myelinated  fibers  in  
both  nerves  and  30% of  teased myelinated fibers were undergoing  axonal degeneration. In 
the splanchnic, but not vague nerve, axonal degeneration and loss of unmyelinated  fibers  
was  observed in Tuck study.  Thus, it appeared, in addition  to  the demyelinating changes, 
an apparent “broadening” of  the pathologic insult  to  include axons of myelinated  fibers and 
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unmyelinated  fibers. Kalimo et al and Morey et al provided further morphologic data on 
rabbit EAN and rat EAN, respectively. In the rabbit study done by Kalimo et al there were 
changes in both  sympathetic and parasympathetic structures with  relative  sparing of  
perikarya, and greater  predilection  for myelinated  structures .44In the rat study of  Morey et 
al  autonomic  involvement was  largely  limited to myelinated structures  in  the vague, but 
not sympathetic  chain.45.  Two physiologic studies of autonomic function in EAN  done by  
Solders et al and Saksa et al almost at the same time and provide evidence that vagal 
neuropathy is an  important feature In GBS. Solders et al. induced EAN in rats and observed,  
in some animals, a reduction in RR variability, mild vagal inflammation and demyelination  
and  slowed conduction  46 where as  Saksa induced EAN  in  rabbits  and observed  a  loss  in  
the bradycardic  response  to  respiratory  strain,  suggesting vagal neuropathy 47.Appenzeller  
et al described  a  distinct  experimental autonomic neuropathy in rabbits using human  
sympathetic  ganglia  tissue.The injected  animals lost  reflex  vasodilation  to  trunk heating 
implying involvement of efferent sympathetic cholinergic fibers. Inflammatory changes were 
also observed in the sympathetic ganglia in this  model.48 
Pathological models of autonomic neuropathy in GBS 
There have been only a few detailed pathologic studies of  the  autonomic nervous  system  
involvement  in GBS available till now. The studies available tend to support the 
physiological evidence that there are independent derangements of sympathetic  and 
parasympathetic output as well as their afferent input. Haymaker and Kernighan reported 
edema and inflammation in the superior cervical sympathetic ganglion in one autopsy 
case.49In Matsuyama and Haymaker study ,vague nerve was showing occasional 
disintegrating ganglion cells, perivascular mononuclear cells, and demyelination where as the 
sympathetic nervous system had similar, but more mild changes. Axons and unmyelinated  
fibers  were  relatively  well  preserved,white  ramie  were  often  involved  but  grey ramie 
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rarely.50Later Birchfield and Shaw'  described chromatoloytic changes  in  the  inter 
mediolateral  cell  column of two autopsied  patients,  one  of whom had postural  
hypotension prior to death  where as one had  abnormal  Valsalva ratio.51 Kanda  et al 
described  a  patient  with GBS who  died  of  sudden  bradycardia in which there were  
"myelin-destructive''  lesions  in  the  sympathetic chains and slight lymphocytic infiltrations 
in  intracardiac ganglia. 52 Bredin et al mention  infiltration  with  inflammatory  cells of  the 
stellate  ganglion  in  one case with  prominent  autonomic instability .53Panegyres et al  
described  a 41-year-old man that died on the twelfth day after onset of GBS from 
hypotension and asystole in which Sympathetic  ganglia  had  chromatolysis,  infiltrates  of 
mononuclear  cells, and nodules  of nageotte,  but there were  also  perivascular  infiltrates  in  
the hypothalamus and brain stem.54 
The Nature of  the Autonomic Deficit: 
Reports  of  autonomic evaluation in patients with GBS has varied  from single case studies 
to prospective investigations, often  of  selected  patients using varying techniques and 
autonomic function test . 
Cardiovascular complication:  
Cardiovascular abnormalities in the GBS are attributed  to autonomic neuropathy and are 
seen variably  upto  2/3 rd of  affected patients.55 
Common benign complications : 
1)Sinus tachycardia  
 
2)Postural hypotension 
 
 3)Minor ECG changes  
 
Serious Complications : 
 
1) Hypertension (sustained, episodic)  
 
 2) Episodic hypotension  
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  3) Sensitivity to vasoactive drug 
 
  4) Bradyarrhythmias (bradycardia, asystole)  
 
   5)Tachyarrhythmias 
 
Alterations  in resting  blood  pressure  measurements and reflex blood pressure changes  
have implied  that  there  is  sympathetic  dysfunction  in GBS. Continuous blood pressure 
recordings have identified  unpredictable  fluctuation of   blood pressure  with  sudden 
episodes  of  cardiovascular collapse. Fluctuations in BP are common and  are thought to be 
characteristic of the GBS, helping to differentiate it from critical illness neuropathy 56 .Truax  
reported hypertension  in 27%  of GBS patients, paroxysmal in 24%,  and sustained  in 3%. 
Paroxysmal  hypertension  in  Truax patient was  correlated with  quadriplegia and 
ventilatory  dependence. 57Sustained Hypertension may be  complicated  by subarachnoid  
hemorrhage, pulmonary edema or PRES.58 Hypertensive  episodes may  be  followed by  
abrupt hypotension  or  sudden death with  extreme sensitivity to vasoactive agents. In 
McQuillan and Bullock study,  systolic pressure  fluctuations for  over  3 min exceeded 50 
mmHg,despite sedation and antihypertensive  in one patient. In Lichtenfeld series,> 60% of 
patients’ had  either  hypertension  or electrocardiographic abnormalities ,  43% had  postural 
hypotension  and episodic  hypotension was seen in 57%.1  patient of Lichtenfeld series of  
patient  had  daily variation between 80/50  to 230/80  mmHg.  Blood  pressure  elevations  in  
Lichtenfeld’s patients  lasted for between  2  and  21  days  from  the onset of  the illness with 
a mean of 7 days but, unlike Truax studies, there was no correlation between hypertension 
and severity of motor weakness 59.In the study by Pfeiffer et al, significant BP decreases were  
seen in about  75% of the patients’ , although none reported any  orthostatic symptoms, while 
patients with BP fluctuations and high diurnal heart rates have been identified as at high risk 
for arrhythmias as well 60,61.So, patients’ with labile BP should undergo prolonged 
cardiovascular monitoring, preferably in an intensive care unit. In patients with hypotension, 
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a fluid challenge is advocated before starting low-dose vasopressin therapy. Presently, there 
are no specific recommendations for target mean arterial pressure. For sustained 
hypertension, the judicious use of anti hypertensive therapy is warranted. Patients with mean 
arterial pressure >125 mm Hg may be treated with intravenous labetalol, small, or 
nitroprusside. Ventilated patients on sedation should also be closely monitored for  sudden 
fall  in BP as well, especially given that the possibility of  enervation hypersensitivity is 
high62 In patient  with labile BP, other contributing conditions, such as pulmonary thrombi 
embolism, sepsis, GI bleed,and metabolic abnormalities also need to be considered. 
Parasympathetic dysfunction: 
 Most of the available studies  suggest  significant  parasympathetic  system  defects  in  GBS. 
Vagal neuropathy  probably  has  received  the greatest attention. Vagal overactivity caused 
by afferent baron receptors reflex failure is believed to be responsible in causing bradycardia. 
Bradyarrhythmias can occur in up to 50% of patients with the GBS, and potentially serious 
events requiring the use  of atropine or pacemaker placement, including atrio ventricular 
block and asystole, have been reported in 7% to 34% of patients 63,64,65these  vagal spells  
may be noted  following  tracheal  suctioning 66 .Acute vagal  deficit  could be responsible for 
tachyarrhythmia, specially sinus tachycardia . In a study by Pfeiffer et al, an increase in the 
mean heart rate to >125 beats/min was documented in about 25% of the subjects. In the MGH 
series, sustained sinus tachycardia was noted in 37% of patients and that was correlating  with  
the degree of motor  weakness, the presence  of  respiratory failure  and  bulbar  involvement. 
Persson and Solders had earlier noticed  a  reduction  in  rate-related  R-R variation with 
normal and deep  breathing  in GBS patients.67Singh et al.reported abnormal 
expiratory/inspiratory  heart rate  ratio in  31.6%  and  an  abnormal Valsalva heart rate ratio 
in 28.6%  of their 24 patients with GBS 68. Bansal et al. noted  reduced  mean  heart rate  
acceleration  to  atropine  in  patients with GBS with  later  recovery  implying a 
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parasympathetic  afferent  defect.69 Other arrhythmias  and  ECG changes  have  been  
frequently   reported  In GBS  patient  including atrial tachyarrhythmias  including  
fibrillation, Flutter, paroxysmal tachycardia, ventricular tachycardia,  elevated  or  depressed  
ST  segments,  flat or inverted  T waves, Q-T  interval prolongation,axis  deviation,  and  
various  forms  of  conduction block70.These Electrocardiographic changes are  believed to be  
secondary to associated myocardial involvement. 
Myocardial involvement: 
The myocardial involvement could range from asymptomatic myocarditis to neurogenic 
stunned myocardium and heart failure. These effects are mainly due to activation of the 
sympathetic nervous system and catecholamine-associated myocardial injury.71 
 Acute coronary syndrome : 
Published literature showed evidence of  acute coronary syndromes, including ST-segment 
elevation myocardial infarction during therapy for the GBS with intravenous 
immunoglobulins,probably related to catecholamine surge.72 
Electrocardiographic changes:  
The electrocardiographic changes do not constitute specific pathology. A wide spectrum of 
electrocardiographic changes have been demonstrated, including giant T waves, prolonged 
QT intervals, ST-T changes, U waves, and atrio ventricular blocks,in addition to 
bradycardia73 . These changes are believed to be secondary to associated myocardial 
involvement. Hence, patients manifesting with bizarre electrocardiographic results should be 
investigated for underlying cardiomyopathy. 
Bladder  and  Bowel  Dysfunction: 
Different degree of Genitourinary system involvement is seen patients with GBS.. Urinary 
retention occurred in 8/ 30 patients’  in Lichtenfelds  series  (30%), 14 of  127  (1 1 %) 
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patients reported by Ravn from Denmark  and 27% of  the MGH series. Ravn  reported  2 of  
127 patients  had  urinary  incontinence 74 .4 cases (2%) in MGH series had overflow 
incontinence, 3 patients had motor paralytic bladders, and  1 had  impaired bladder 
sensation52. Wheeler  et  al. reported  3 patients  with  detrusor  areflexia, a positive 
bethanechol super sensitivity  test  and  electromyographic evidence of neuropathy involving 
perineal muscles.75Constipation are noted  in  14% of  the MGH  series. Fecal incontinence 
are reported in  two patients  of MGH series and 6 patients of Ravn series 59,74 
Sweating abnormalities: The presence  of  anhidrosis in some GBS patient showed 
impaired sympathetic output  and was reported   in 7 patients  by the  Tuck and McLeod 
series of patients.7 Hyperhidrosis has also been identified in other series, as has been 
anhidrosis. Lichtenfeld also  describes  episodes  of  facial  flushing,chest  tightening,  and  
bradycardia  attributed  to parasympathetic  overactivity59. 
Sympathetic skin response(SSR ) : 
SSR is a test of sudomotor function and represents the changes in potential recorded from the 
surface  of  skin following various internal or external stimuli. It is a non invasive methods 
and can be used to assess the integrity of the sympathetic sudomotor.SSR  is a polysynaptic 
reflex that is activated by a variety of afferent inputs. The efferent part of reflex arch 
consisted of myelinated sympathetic fibers of neurons from intermediolateral nucleus in T1  
to L2 part of spinal cord that terminate in paravertebral sympathetic ganglia. The post 
ganglionic fibers are non myelinated (type C fiber) and innervate the eccrine sweat gland. 
So,the effector of reflex arch and most probably generator of potential change are activated 
eccrine sweat glands with cholinergic mediation. The reflex is coordinated in the posterior 
hypothalamus, upper brain-stem reticular formation and spinal cord. Thus, central or 
peripheral lesions of the sudomotor system can impair the SSR, but most frequently  used in 
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diagnosing the functional impairment of non myelinated  post ganglionic sudomotor 
sympathetic fiber in peripheral neuropathy. 
Methods of SSR :  
The methods of SSR recording was first introduced in electrophysiological laboratory by 
Shahani in 1984.SSR may be elicited either directly or reflexly.The direct response is 
obtained by stimulating a peripheral nerve but not used in clinical practice frequently  due to 
high threshold  of sympathetic  trunk for activation of unmyelinated C fibers and 
simultaneous activation of pain fibres.The other methods commonly used in practice are deep 
inspiration ,coughing or starling sound as described by Shahani et al. 
 
Figure1: Showing  Neural components of the thermoregulatory system. 
Technique of SSR:  
The recording of SSR is being done at normal ambient temperatures, relaxed state, without 
acoustic disturbances . The standard   surface Ag-Ag Cl electrodes  are used for recording  
and are placed on the palm (active) and referenced against the volar forearm or dorsum of the 
hand,and on the sole of the foot (active) and referenced against the shin or dorsum of the 
foot.The ground electrode is proximal to the recording electrodes. Simultaneous bilateral 
recording from upper and lower extremities is recommended. 
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The study  of SSR used an EMG machine with filter setting of low frequency at 0.2HZ and 
high frequency at 500HZ and sweep speed at 1 second per division.  
The  SSR can be evaluated either qualitatively or quantitively. In clinical practice qualitative 
evaluation is preferred and accept only absence of SSR as a pathological. The quantitative 
evaluation using latency prolongation or reduction of amplitude as a  parameters is used in 
some laboratories,  but  difficult to interpret the result due to the variation of results in 
different conditions’ and  different time in the same person. 
There are only two studies available on SSR abnormalities in GBS. Taly AB et al76 studied 
SSR abnormalities in 24 GBS patients of which nine had absent SSR.13/24 patients’ were 
showing evidence of clinical dysautonomia, of whom five had absent SSR..Five patients of 
Taly series were showing features of predominant axonal damage  with preserved SSR.  
Deniz and Yerdelen 77 studied 14 patients  with GBS, among whom  13 had AIDP and one 
had AMAN.Out of 14 patients ,SSR could not be elicited  in two patients including one 
AMAN but in the rest of the  12  patients ,amplitude of SSR was found to be decreased  when 
compared with control subjects(P=0.004).Both these studies showed  SSR abnormalities are 
common in GB syndrome and may be complementary to bed-side tests for autonomic 
dysfunction. 
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MATERIALS AND METHODS 
Eight GBS patients admitted between July 2010 to March 2011 in the Department of 
Neurology, Christian medical college ,Vellore were recruited into the study after obtaining  
IRB Clearance and tests of autonomic function were performed on them.The test battery 
consisted of Resting heart rate and RR interval variability following deep breathing(RRIV) 
and on standing ,Resting BP  and BP response to standing for three minutes and immersion in 
cold  water ,  cardiac response to Valsalva  maneuvers and SSR(sympathetic skin response) . 
The presence of  fluctuation of pulse and BP over 24 hours, sweating abnormalities  and 
bladder and bowel dysfunction were also recorded. The patient’s disability at the time of 
testing were graded on a scale from 0 to 6 (Hughes functional grade) Status Criteria: 
0                                    Normal            
I                                      Minimal sign and Symptoms ,able to run 
2                                     Ambulates independently 
3                                     Moderate disability,able to walk 5 met with aid 
4                                     Bed bound 
5                                   Required assisted respiration  
 6                                      Dead 
INCLUSION CRITERIA: 
All  patients at or above 18 years of age who satisfy the diagnostic criteria for    typical 
Guillain Barre syndrome was included for the study. 
Diagnostic criteria for typical Guillain Barre syndrome :-     :-  
Features required for diagnosis : 
   1.Progressive weakness in both arms and both legs   
   2. Areflexia  
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Features strongly supporting diagnosis :-  
  1.Progression of symptoms over days to four weeks  
 
   2. Relative symmetry of symptoms   
 
  3.Mild sensory symptoms or signs  
 
 4. Cranial nerve involvement especially bilateral weakness of facial    muscles     
 
 5 .Recovery beginning 2- 4 weeks after progression ceases  
 
  6. Presence of autonomic dysfunction  
 
 7.Absence of fever at onset  
 
 8. High concentration of protein in cerebrospinal fluid with < 1   cells  
 
Features  casting doubt on the diagnosis : 
1. Marked  persistent asymmetry of weakness.  
 
2. Persistent bladder or  bowel  dysfunction.  
 
3. Bladder or  bowel  dysfunction  at onset.  
 
4 .More  than 50 mononuclear  leukocytes/mm3  in  CSF.  
 
5. Presence of  polymorphonuclear  leukocytes  in  CSF.  
 
6. Sharp sensory  level.    
 
NEUROPHYSIOLOGICAL CRITERIA:-  
 I used   modified  Cornblath et al. criteria for  electrophysiological diagnosis of GBS78 
AIDP :At least one of the following in each of at least two nerves or at least two of the 
following in one nerve if all others inexcitable and d CMAP > 10 % LLN: 
Motor conduction velocity   <   90% LLN   ( 85  % if d CMAP  <  50 % LLN) 
Distal motor latency    > 110 % ULN   (> 120 % if dCMAP  <  100 % LLN) 
pCMAP  /  dCMAP  ratio    <  0.5  and dCMAP   > 20 % LLN 
  F-response latency               > 120%   ULN       
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AMSAN :-None of the features of AIDP except one demyelinating feature allowed in one 
nerve if dCMAP < 10 % LLN 
Sensory action potential amplitudes < LLN 
AMAN :-None of the features of AIDP except one demyelinating feature allowed in one  
nerve if dCMAP < 10 LLN 
 LLSensory action potential amplitudes normal 
Inexcitable: dCMAP absent in all nerves or present in only one nerve with dCMAP <10%  
LLN 
(dCMAP=compound muscle action potential amplitude after distal stimulation; pCMAP=compound 
muscle action potential amplitude after proximal stimulation; LLN=lower limit of normal. 
ULN=upper limit of normal. ) 
EXCLUSION CRITERIA : 
1.Patients’having any symptoms suggestive of peripheral neuropathy before the development 
of GBS. 
2.Comorbidities like Diabetes mellitus ,Hypertension ,Coronary artery or heart      
disease,Thyroid diseases  
3) Human immunodeficiency  virus infection  
 4) Collagen vascular disease  
  5) Neurotoxic drugs or toxin exposure  
  6)  Porphyria  or Alcoholism 
 as determined by a detailed  history examinations and relevant tests’,which may affect the 
autonomic nervous system  or  resting  heart rate or blood pressure,were not included in this 
study. 
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Methods : 
Autonomic function tests was carried out by using  
1)  Philips bed side ECG monitor 
 
2)  Pulse Oximeter 
 
3)Sphygmomanometer 
 
All the patients were closely observed for the symptoms and sign of autonomic dysfunction 
including continuous recording of heart rate and blood pressure using Philips bed side ECG 
monitor.All the data of resting HR and BP, trends of HR and BP over 24 hours and battery of  
autonomic function test conducted  were retrieved once every 24 hours for the first three days 
of admission followed by once every week . The recording was continued until the first 4 
weeks of illness or improvement by 1 functional grade (Hughe’s grading), whichever was 
earlier.  
Procedure of autonomic evaluation.   
Resting HR: 
Resting HR were recorded when the patient lies in supine position for ten minutes prior to the 
test. 
Resting BP: 
 Resting systolic and diastolic blood pressure were recorded from brachial artery   with the 
help of Mercury sphygmomanometer with cuff applied to the right or left arm.Tachycardia 
was defined as HR> 100 beat/min and bradycardia as  HR<60 beat/min 
Labile  HR and BP: 
Fluctuation of HR and BP(labile) were recorded with the help of continuous Philips bed side 
ECG monitor with setting of every 15 min during first three days of admission followed by 
every 30 minutes till the termination of studies..Fluctuation was considered significant (labile 
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HR and BP) when fluctuation of systolic BP was >40 mm Hg/day and HR >30 beat/min in a 
day.79 
HR  response to deep breathing/I-E  Difference  (I-E): 
The  patients were  instructed  to breathe deeply at a rate of 6 breaths/min in the sitting 
position. The maximum and minimum R-R intervals were measured during each breathing 
cycles and converted to beats per minute. The result was then expressed as mean  of the 
difference between maximum and minimum heart rate for six measured cycles in beats per 
minute. Deep breathing difference(DBD/I-E differences)=mean of  heart rate differences in 6 
breath cycles and considered abnormal according to age dependent values.80 
HR Response to active change of posture(30/15  RATIO): 
  The patient was observed for  5 minutes of quiet breathing, following which the patient  was 
asked  to stand up as quickly as possible,un aided . The ratio  of  the  longest  RR  interval  
around  the  30th beat after standing to shortest RR interval around 15th beat reflect 30/15 
ratio.A ratio of 1.00 or less was defined as an abnormal response, 1.01-1.03 as borderline and 
1.04 as normal response.80 
HR variation to Valsalva Maneuver/ Valsalva ratio  (VR).  
 After  30  minutes of  rest  in  a  lying position with 30 degree head-up tilt,  the patient was 
asked  to blow into a mouthpiece connected to a mercury sphygmomanometer and  maintain  
a pressure  of  about 40 mmHg  for  15  seconds. The  ratio of  the  longest  RR   interval 
within 40 beats  after  the maneuver  to  the  shortest RR interval  during  the maneuver will 
be  taken  and  the maximum response of  three  successive maneuvers will be  recorded. The 
heart rate changes induced by the Valsalva maneuver was expressed as the ratio of  the 
maximal tachycardia during the maneuver to the maximal bradycardia after the  maneuver. 
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This ratio was defined as the Valsalva ratio and was calculated as the ratio of maximum R-R 
interval after the maneuver to minimum R-R interval during the maneuver. 
Valsalva ratio(VR)= maximal tachycardia/maximum bradycardia= maximum R-R 
interval/minimum R-R interval.  
A value of 1.10 or less was defined as an abnormal response, 1.11-1.20 as borderline, and 
1.21 or more as a normal response.81 
Postural changes in systolic BP (where feasible): 
The patient was asked to rest in a supine position for 5 minutes and the resting BP was 
recorded. The patient was then asked to stand unaided, and remain  standing unsupported for 
3 minutes. The difference between the resting and standing BP levels was calculated. The fall 
in systolic BP of 30 mm Hg or more was defined as abnormal, fall between 10-29 mm Hg as 
borderline and a fall less than 10  was considered normal.82 
Hand immersion test: 
After  resting  in a lying position  for  5 minutes, one hand was immersed in Ice Cold water 
for 2 minutes or as long as the subject could tolerate. A  rise  of  the diastolic blood of >15 
mm Hg  was  considered  normal, and values of  1 1 to 15  mm Hg as borderline.82 
Sympathetic skin response test ( SSR) : 
SSR were done in all of our patients with the help of EMG  machine (Nicolet Viking 
electro diagnostic system).Study  were done in relaxed and awake state with skin temperature 
24- 320c using EMG machine with filter setting of low frequency at 0.2HZ and high 
frequency at 500HZ and sweep speed at 1 second per division using deep inspiration for 
electrical stimulation.I used standard surface Ag-AgCl electrodes  for recording  and placed 
on the palm (active) and referenced against dorsum of the hand for upper limb and on the sole 
of the foot (active) and referenced against the dorsum of the foot for lower limbs.  
Simultaneous bilateral recording from upper and lower extremities was done . If deep 
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inspiration failed to elicit SSR in the first pass, a second attempt was made after a gap of 5 
minutes to overcome habituation.  A minimum of three attempts were made before declaring 
it as absent SSR.  Failure to elicit SSR with deep inspiration even after 3 attempts was 
considered as abnormal test.   
Sweating abnormalities:  The symptoms and sign of sweating abnormalities 
were recorded including areas of anhidrosis, hyperhidrosis,episodic flushing,cold or warm to 
touch. 
Bowel and bladder  dysfunction: The symptoms and sign of bladder and bowel 
dysfunction were recorded  with help of history and  relevant clinical test . 
Longitudinal Study  of Autonomic  Function: 
The battery  of Autonomic function test  was performed  once daily  for first three days of 
admission,first preferably within 24 hours  followed by once  every weeks . The recording 
was  continued till  first 4 weeks of illness or improvement  by 1 functional grade (Hughe’s 
grading), whichever was earlier.  To exclude major  circadian variations,  the procedures 
were  always done between  10.00  and  16.00 hours. 
STATISTICAL METHODS  
Statistical analyses were performed with SPSS (windows 11.5 version, SPSS inc, Chicago), for all 
variables and descriptive statistics were  calculated .Data were  expressed as mean + SD unless  
indicated  otherwise. The analysis and comparisons  of clinical characteristics were done by 
chi-square test. The differences between disease stages were analyzed by two tailed unpaired 
t test. Results were  considered  statistically  significant  for p value of  < 0.05. 
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RESULTS 
Patient’s clinical and biological characteristics 
After applying the inclusion and exclusion criteria, a total of 8 patients were included for 
longitudinally performed autonomic function tests (ATs). This comprises 5 (62.5%)males and 
3(37.5%) females. The mean age of these patient were 35.37 ± 15.20 years (range, 18-60 
years).The mean Hughes disability score(DS) at admission was 3.75 (range, 2-5; median 
4).The mean duration of illness at the time of presentation was 3.75 ±2.05 days where as  
mean duration of  the  progressive phase(onset to nadir ) was 9.37 ±6.09 days, ranges from 
<36 hours to 20 days. Out of the eight patients, 7 had AIDP and remaining one patient had 
AMAN.Two patients (25%) had required mechanical ventilation. Mechanical ventilation was 
started on the day of admission (2nd day of illness) in one patient and was required for 3 
weeks where as in other patient it was started on 6th day of admission (9th day of illness) and 
continued for 100 days. All the patients of study group were taken for plasma exchange and 
variable number and amounts of exchanges were done (Minimum 3.5L/4 cycle and 
Maximum 8L/8 Cycles) but in one patient (patient 3), IVIG was given following intolerance 
to PE 
.Antecedent Events: Out of eight patients, two had history of myalgia and fever , 2 
had  history of diarrhea and one had history URTI an interval ranging from 10 to 21 days  
prior to  onset of illness . 
Cranial Nerve Involvement: Six patients had bifacial weakness,4 bulbar weakness 
along with bifacial weakness, none having ophthalmoplegia or isolated bulbar involvement. 
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Sensory symptoms or sign: History of painful sensory paresthesia of limbs was 
obtained in 6 patients.One patient was detected to have a stocking pattern of sensory loss  
CSF studies:CSF study  was  done in all patient, usually within 24 hour of admission. 
Out of 8 patient, 6 had  a CSF protein of>45mg/dl  with albumin cytological dissociation. 
Figure2.  Showing  distribution of age 
 
 
Figure 3.Showing time required to reach onset to nadir  
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Figure 4. Showing Hughes functional grade at admission & discharge/ 
                  termination of study 
 
 
 
 Table.1 Showing duration of illness at presentation      
 
 
 
 
 
 
 
Duration Frequency percent 
24 h-36h 2 25 
36h-72h 2 25 
72h-7d 3 37.5 
8 d-14 d 1 12.5 
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Table 2.Showing clinical characteristics of patients 
Characteristics Minimum Maximum Mean SD 
Age 18 60 35.50 15.20 
Days  of illness at 
presentation  
2 8 3.75 2.05 
Disability score at 
presentation 
2 5 3.75 0.88 
Disability  score at 
discharge/termination of 
study  
2 5 3.12 0.83 
Onset to nadir in days 1 20 9.37 6.09 
Table 3. Showing antecedent Events 
 
Events Frequency 
 
Percent 
 
Diarrhea 
 
2 25 
Fever  and  
Myalgia 
2 25 
URTI 1 12.5 
Nil 3 37.5 
 
Table 4 Showing cranial nerve involvement 
Cranial nerve frequency Percent 
Bifacial involvement 6 75 
Bulbar involvement 4 50 
Nil 2 25 
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Table 5.Showing sensory symptoms/sign 
 
Frequency Percent 
Painful paresthesia 6 62.5 
Sensory loss 1 12.5 
Nil 2 25 
 
Symptoms and clinical sign of autonomic dysfunction 
During the study period, a history of symptoms of autonomic dysfunction was 
noted,clinical cardiovascular manifestation of autonomic dysfunction was 
recorded and battery of autonomic function test  were performed . Due  to 
mechanical ventilation, motor disability, or facial  or bulbar paresis, the  
complete battery  of autonomic function test  could not  be  applied  to  every  
patient.  7/8 patients (87.5%) had evidence of  dysautonomia of variable  
severity during the course of their illness. 
Symptoms of autonomic dysfunction: 
Postural dizziness was reported in two patients. In one patient postural dizziness preceded the 
onset of motor weakness by 5 days and this symptom was very prominent and persisted  upto 
10 weeks after the onset of neuropathy inspite of improving motor weakness.The bowel 
dysfunction was observed in 4/ 8 patients, 3 had history of constipation where as one had 
both constipation and urinary retention..One patient had history of constipation 3 days 
preceding the motor weakness where as one had urinary hesitancy 1 day prior to onset of 
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motor weakness.The sweating abnormalities was detected in 3 patients.Two patients were 
showing anhidrosis of both lower limbs below knee joints where as  in one patient  anhidrosis 
of both lower limbs below ankle joint was seen during first 2 weeks followed by episodes of 
hyperhidrosis of different part of body including  both lower limbs,trunk and face and 
persisted upto 4th weeks of illness.   Palpitation and increased thirst  were seen  in one patient. 
Table 6 Showing symptoms of autonomic dysfunction : 
symptoms Frequency Percent 
Constipation 4 50 
Anhidrosis 3 37.5 
Postural dizziness 2 25 
Palpitation 1 12.5 
Increased thirst 1 12.5 
Urinary retention 1 12.5 
Hyperhidrosis 1 12.5 
Nil 2 25 
 
Table7. Showing symptoms of dysautonomia before onset of motor          
 
           weakness 
Symptoms Number 
 
Percent 
 
Cumulative 
percent 
Dizziness 1 12.5 12.5 
Constipation 1 12.5 25 
Urinary hesitancy 1 12.5 37.5 
Nil 5 62.5 100 
 
33 
 
 
Table 8. Showing bladder and bowel  dysfunction: 
 Frequency Percent 
Bowel dysfunction 
(constipation) 
4 
 
50 
Bowel   (constipation)  
& bladder  dysfunction 
(retention) 
1 12.5 
Nil 4 50 
 
Table 9.Showing sweating abnormalities 
 
Frequency Percent 
Nil 5 62.5 
Anhidrosis of lower limb 3 37.5 
Episodic hyperhidrosis 1 12.5 
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Clinical cardiovascular manifestation of autonomic dysfunction 
Sinus tachycardia: 
Sinus tachycardia was most common abnormality and was detected in seven of 8 
patients’(87.5%) The heart rate  of eight patients’ ranged  from 50-152 beat/min .Tachycardia 
persisted for 2 weeks in one patient,3 weeks in 5 patients and upto 4th weeks in one patient. 
Sinus bradycardia: 
Three patients’ had episodes of sinus bradycardia which lasted for 1 Week in one patient and 
for two  weeks in 2 patient. 
Labile HR: 
High diurnal variation of HR(>30 beat/min) was observed in 75% of patients.The maximum 
fluctuation of HR in a single day was recorded 102.Labile HR persisted for 1 week in one 
patient,2 weeks in one patient ,3 weeks in three  patient and upto termination of study ( 4th 
week) in one patient. 
Hypertension: 
Hyprtension of variable severity was detected in 6 patient,none of whom were known to be 
hypertensive prior to this illness .It persisted for  1 week in one patient ,2 weeks in 3 patients 
,where as in other  two patients  upto 3rdweeks. The hypertension was persistent in 5 patients 
and paroxysmal in one patient. The maximum systolic and diastolic BP recorded in our 
patient  was 200 mmHg  and 152 mmHg respectively.None of our patients having evidence 
of persistent of severe hypertension or hypertensive crisis as reported earlier and  not treated  
except one patient as beta blocker and antihypertensive might aggravate incipient 
hypotension and bradycardia. One  patient was treated with low dose of beta blocker and 
tolerated  well without significant fall of BP and HR. 
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Hypotension: 
The episodes of hypotension was observed in four patients and persisted  upto 2nd week of 
illness. Hypotension was spontaneous in three of 4 patients’ ,usually preceded  by highly 
labile blood pressure. Although spontaneous hypotension was not observed in one patient,but 
she had hypotensive episodes during plasma exchanges and on  active change of posture .In 
other two patients having evidence of  hypotensive episodes both spontaneously and during 
plasma exchanges.The minimum  systolic and diastolic Blood pressure recorded in our 
patient was 54 mmHg and 40 mmHg respectively. 
Labile BP: 
High diurnal variation of blood pressure(>40 mmHg within single day) was observed in 6 
patient. The maximum fluctuation of systolic BP recorded in single day was  144 mmHg . 
Fluctuation of HR and BP during PE: 
The significant fluctuation of HR and BP was observed in four of 8 patient who received 
PE.The most common type of abnormalities detected was episodes of tachycardia and 
hypotension requiring frequent  IV fluid challenge and termination of procedure .In one 
patient, as the episodes of hypotension was very frequent and severe, PE was discontinued 
and IV Ig was started. 
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Figure 5.Showing clinical cardiovascular manifestation of autonomic  
dysfunction 
 
 
Table 10 Showing fluctuation of  HR and BP during PE: 
 
 Frequency Percent 
Significant fluctuation of HR 
& BP 
4 50 
Hypotensive episode 3 37.5 
Needs termination of procedure 3 37.5 
Discontinuation of PE 1 12.5 
Nil 4 50 
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Table 11.Showing clinical cardiovascular manifestation of autonomic   
dysfunction.Mean(maximum-minimum)   
 
 
Pt number 
 
 
 
Mean Resting 
HR  
 Mean 
fluctuation  of  
HR  
 Mean  systolic  
BP 
 
Mean 
fluctuation of 
systolic BP 
 
1 
113 ( 86-130 ) 69(54-90) 150.3(122- 166) 52.8(7-78) 
2* 91.2(  74-110)     24.4(20-30) 100.8(90-108) 20.8(14-26) 
 
3 
110.6 ( 92-130) 48.1 (18-68) 157.6(140-188) 81.66(49-146) 
 
4 
112( 104-120)         52.2(38-62) 145.6(128-170) 44(30-80) 
5 102(76-114)        45.6 (22-62) 149.6(120-170) 62.66(22-100) 
6** 90( 78-100) 21.6(14-30) 118.4(110-126) 27(18-34) 
7 
 
114(108-120 ) 41(24-70) 150(134-162) 58.6(20-101) 
8 
 
113.6 (92-136)       53.6(34-80 148.8(110-166) 48.4(20-64) 
 
*Although, clinical cardiovascular sign of dysautonomia was absent in this patient but she 
had significant symptoms of postural dizziness, hypotensive episodes during PE and on 
standing and presence of abnormalities on bed side cardiovascular autonomic function test. 
*Patient not having autonomic dysfunction 
 
 
 
 
 
 
 
38 
 
Table 12 Showing trends of clinical cardiovascular function(mean) 
 1stweek (n=7) 2ndweek(n=8) 3rd week(n=8) 4th week(n=4) 
Resting HR 
 
112.33(8.54) 114.57(16.27) 98.28(12.51) 91(14.28)) 
Fluctuation of 
HR over 24 hs 
54.66(16.90) 52.14(18.47) 36.57(11.29) 32.25(19.05) 
Systolic BP 
 
147(24.74) 142(18.72) 133.42(24.91) 131.50(7.54) 
Diastolic BP 
 
91.66(18.04) 96.57(21.56) 79.42(8.38) 77(11.37) 
Fluctuation 
of SBP over 24 hs 
60(28.92) 51.57(18.79) 40.57(25.63) 35.75(17.85) 
 
 
 
Figure 6.  Showing mean resting HR 
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Figure 7.Showing mean fluctuation of HR 
 
 
 
Figure 8.Showing mean systolic BP 
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Figure 9 Showing mean fluctuation of systolic 
BP
 
 
 
Figure 10. Showing trends of clinical cardiovascular function in   
patients with dysautonomia  
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Table 13 showing  Cardiovascular manifestation of autonomic 
dysfunction 
Abnormalities N percent 
1) Rhythm 
abnormalities           
                                  
Sinus tachycardia-
Bradycardia 
  -Labile HR                             
 
 
 
 
 
7 
 
3 
 
6 
 
 
 
 
 
87.5 
 
37.5 
 
75 
2)BP variability 
-Hypertension 
-Hypotension 
 -Labile hypertension 
 
6 
 
4 
 
6 
 
 
 
 
75 
 
50 
 
75 
3)ECG changes 
       ST change 
 
2 
 
 
 
25 
 
 
 
 
 
Table 14.  Showing bed side Autonomic function test 
Autonomic 
function test 
Number 
of 
patient 
test 
done 
Criteria of 
abnormality 
Number of pt  with    
abnormal   response 
 
% of 
abnormal 
response 
Abnormal Border 
line 
abn. 
Total 
HR response                               
 Response to deep   
breathing  (I -E 
differences) 
             
 
                                          
-   30/15                              
ratio   on                          
                            
Standing 
 
6 
 
 
 
 
 
 
4 
 
 
 
 
-Age dependent      
    values 
 
 
 
 
-Abnormal ≤ 1.01 
-Borderline 
abnormal= 
1.01-1.03 
 
3 
 
 
 
 
 
 
1 
 
 
 
0 
 
 
 
1 
 
 
3 
 
 
 
2 
 
 
50 
 
 
 
 
 
 
50 
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                          - 
Valsalva                                       
                            
ratio 
 
 
 
 
2
 
 
 
 
-Abnormal ≤ 1.10 
-Borderline 
abnormal= 
1.11-1.20 
 
 
 
 
1 
 
 
 
0 
 
 
 
1 
 
 
 
 
 
50 
BP response      
 
 -Rise of  
diastolic                                           
    BP in cold                   
immersion  test      
 
                        
 
 
 
 -Change of 
systolic BP on 
standing  upto          
3 min.     
 
 
 
 
 
 
8 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
-Abnormal≤ 10 mm  
Hg rise of diastolic 
BP 
-Border line 
abnormal 
=11-15mmHg rise of 
diastolic BP 
 
 
-Abnormal= Fall of 
systolic BP by l≥ 30 
mmHg 
-Borderline 
abnormal= Fall of 
systolic BP between 
10-29 mmHg 
 
 
3 
 
 
 
 
 
 
 
 
 
1 
 
 
2 
 
 
 
 
 
 
 
 
 
1 
 
 
5 
 
 
 
 
 
2 
 
 
62.5 
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Table 15.Bed side autonomic function test (worst result of each patient 
on longitudinal study) 
Patient Number  
  
1 2 3 4 5 6 7 8 
30:15 ratio ND 1 ND ND ND 0 2 0 
E:I ratio ND 0 2 2 ND 0 2 0 
Valsalva ratio ND 0 2 ND ND ND ND ND 
Fall of systolic BP 
on standing 
ND 2 ND ND ND 0 0 1 
Cold immersion test 2 2 2 1 0 0 0 1 
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Not done= ND,Normal=0,border line abnormal =1,abnormal =2 
Table 16 Showing Sympathetic skin response  test (SSR)  : 
 Frequency Percent 
Absent 5 62.5 
Present 3 37.5 
Total 8 100 
 
Normalized Total Autonomic Score (NTAS) 
On the basis of history,clinical cardiovascular sign of autonomic dysfunction,cardiovascular  
autonomic function test (testing both sympathetic and parasympathetic arm of ANS),  
presence or absence of bladder,bowel and sudomotor dysfunction a normalized total 
autonomic score (NTAS) was obtained by scoring each variable of autonomic dysfunction  as 
below. 
    Variables                                                  Score 
1) Symptoms  of autonomic dysfunction                   Nil =0, Yes =1 
  2) Clinical sign of autonomic dysfunction 
                  Resting HR                                Normal=0,tachycardia or bradycardia =1, 
                                                                      Both tachycardia and bradycardia  =2 
               Fluctuation of HR Over 24 hs            Normal =0, Yes =1   
                Resting    BP                                         Normal=0,hypertension/hypotension =1 
 
                                                                          Both hypertension and hypotension  =2 
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           Fluctuation of systolic BP over 24 hrs            Normal =0, Yes =1 
          Fluctuation of HR and BP during PE                    Normal=0, Yes =1 
                                                         (Hypotension/ hypertension/tachycardia/bradycardia) 
                                                             Intolerance to PE(Discontinuation of PE)=2 
1) Test of Parasympathetic function              
               30:15  ratio              Normal or not done =0,border line abn =1,abn.=2 
             I-E differences.           Normal or not done =0, borderline abn.=1abn.=2                                
             Valsalva ratio              Normal or not done =0,border line abn =1,abn.=2 
 
2) Test of  Sympathetic function                                
Fall of systolic BP on standing         Normal or not done =0,border line abn =1,abn.=2 
              Cold immersion test                Normal or not done =0,border line abn =1,abn.=2 
3) Bladder & bowel dysfunction                    
    Bladder  or  Bowel dysfunction        Nil =0, yes =1 
                                                                       Both  Bladder &  Bowel dysfunction    =2 
6) Sudomotor dysfunction             
                                          Sweating abnormality               Nil =0, Yes =1  
                                           SSR test                                    Normal =0, Yes =1 
                                            Both sweating and SSR abnormalities       =  2 
4) ECG changes                                                           NO=0,yes=1 
Maximum  score  = 24 
These score were added together for each patient and normalized to a 24 point normalized 
autonomic score where one or more autonomic function test could not be performed. 
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Table 17 .Showing Suggested Normalized  total Autonomic score (NTAS)            
classifying degree of dysautonomia     
 
 
 
 
 
 
 
Table 18.Showing Normalized total autonomic score (NTAS) in the 1st week 
of illness 
Patient Number  
  
1 2 3 4 5 6 8 
Autonomic 
symptoms 
0 1 0 0 1 0 0 
Resting HR  2 1 2 2 1 0 1 
Resting BP 2 0 2 1 2 0 1 
Fluctuation of HR 
Over 24 hs 
1 0 1 1 1 0 1 
Fluctuation of 
systolic BP over 24 
hs 
1 0 1 1 1 0 1 
Fluctuation of HR 
and BP during PE 
0 1 2 0 0 0 0 
30:15 ratio ND 1 ND ND ND ND ND 
I-E differences ND 0 2 2 ND 0 0 
Degree of dysautonomia Normalized autonomic score 
Mild  dysautonomia                                    <10 
Moderate dysautonomia 10-16 
Severe  dysautonomia               >16 
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Valsalva ratio ND O 2 ND ND ND ND 
Fall of SBP on 
standing upto 3 min. 
ND 2 ND ND ND ND ND 
Cold immersion test 2 2 2 1 0 0 0 
Bladder &Bowel 
dysfunction 
0 0 0 2 1 0 1 
Sudomotor 
dysfunction 
1 0 1 2 0 0 0 
ECG changes 0 0 1 1 0 0 0 
Total  9 8 16 13 7 0 5 
Normalized total 
Autonomic 
score(NTAS) 
13.5 8 19.2 17.33 10.5 NA 6.6 
 
Table 19.Showing Normalized total  autonomic score (NTAS) in  
2nd week of illness 
Patient Number  
  
1 2 3 4 5 6 7 8 
Autonomic 
symptoms 
0 1 0 0 0 0 1 0 
Resting HR  2 0 1 2 1 0 1 1 
Resting BP 1 0 1 1 1 0 1 0 
Fluctuation of HR 
Over 24 hours 
1 0 1 1 1 0 0 1 
Fluctuationof SBP 
over 24 hours 
1 0 1 0 0 0 0 1 
Fluctuation of HR 
and BP during PE 
0 0 ND 0 1 0 1 0 
30:15 ratio ND 1 ND ND ND 0 2 ND 
I-E differences ND 0 2 ND ND 0 2 0 
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Valsalva ratio ND 0 2 ND ND ND ND ND 
Fall of SBP on 
standing upto 3 min. 
ND 2 ND ND ND 0 ND ND 
Cold immersion test 2 2 2 1 0 0 0 1 
Bladder &Bowel 
dysfunction 
1 0 0 2 0 0 0 1 
Sudomotor 
dysfunction 
1 0 1 2 0 0 1 1 
ECG changes 0 0 1 0 0 0 0 0 
Total 9 9 12 10 4 0 9 6 
Normalized  total 
autonomic 
(score(NTAS) 
13.5 6.26 16 13.33 6 0 10.8 7.5 
 
Table 20.Showing Normalized total autonomic score (NTAS) in 3rd 
week of illness 
Patient Number 
  
1 2 3 4 5 6 7 8 
Autonomic 
symptoms 
0 1 1 0 0 0 1 0 
Resting HR  1 0 1 1 1 0 1 0 
Resting BP 1 0 0 1 0 0 1 0 
Fluctuation of HR 
Over 24 hrs 
1 0 1 1 0 0 0 1 
Fluctuation of 
systolic BP over 
24 hs 
1 0 1 0 0 0 0 0 
Fluctuation of HR 
and BP during PE 
0 0 0 0 0 0 0 0 
30:15 ratio ND 0 ND ND ND 0 1 0 
I-E differences ND 0 2 1 ND 0 2 0 
Valsalva ratio ND 0 1 ND ND ND ND ND 
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Fall of SBP on 
standing upto 3 min. 
ND 2 ND ND ND 0 0 1 
Cold immersion test 1 2 2 1 0 0 0 1 
Bladder &Bowel 
dysfunction 
0 0 0 0 0 0 0 0 
Sudomotor 
dysfunction 
1 0 1 1 0 0 1 1 
ECG changes 0 0 1 0 0 0 0 0 
Total 6 6 11 6 1 0 7 4 
Normalized  total 
autonomic 
score(NTAS) 
10.2 6 14.66 8 1.71 0 8.4 4.4 
 
 
Table 21.Showing Normalized total autonomic score (NTAS) in 4th 
week of illness 
Patient Number  
  
1 3 5 7 
Autonomic symptoms 0 0 0 1 
Resting HR  1 0 0 1 
Resting BP 0 0 0 0 
Fluctuation of HR Over 24 
hs 
1 0 0 0 
Fluctuation of systolic BP 
over 24 hs 
0 1 0 0 
Fluctuation of HR and BP 
during PE 
0 0 0 0 
30:15 ratio ND ND ND 1 
I-E differences 1 ND 0 1 
Valsalva ratio ND 1 ND ND 
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Fall of SBP on standing upto 
3 min. 
ND ND ND 0 
Cold immersion test 0 1 0 0 
Bladder &Bowel dysfunction 0 0 0 0 
Sudomotor dysfunction 2 1 1 1 
ECG changes 0 1 0 0 
Total 5 6 1 5 
Normalized total autonomic 
score 
6 8 1.71 6 
 
 
 
Table 22.Showing trends of Normalized Total Autonomic Score in 
weeks 
Pt Number Ist week 2nd week 3rd week 4th week 
1 13.5 13.5 10.2 6 
2 8 6.26 6 NA 
3 19.2 16 14.66 8 
4 17.33 13.33 8 NA 
5 10.5 6 1.71 1.71 
7 NA 10.8 8.4 6 
8 6.6 7.5 4.4 NA 
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Figure 11. Showing trends of Normalized Total Autonomic Score in 
weeks 
 
 
Table 23 Showing Normalized  total autonomic score in different stages of 
patient with  autonomic dysfunction 
Pt number At presentation Progressive stage Plateau stage Remission stage 
1 13.5 13.5 10.2 6 
2 8 8.35 6.26 6 
3 19.2 16 14.66 8 
4 17.33 ND# 13.33 8 
5 10.5 6 1.71 NA* 
7 10.8 8.4 6 NA* 
8 6.6 7.5 6.6 4.4 
*All presented in progressive stage of the illness,two patients(5,7) was in plateau stage at the 
time of termination of study 
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#Attained  nadir within 72 hrs. of illness 
Figure  12. Showing NTAS different stages of patient with autonomic dysfunction 
 
 
APR=At presentation,PRS=progressive stage,PLS=plateau stage,RES =Remission stage 
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Table 24. Showing Comparison  autonomic dysfunction in GBS with available 
studies 
Variable Tuck and 
Mcleod 7 
Flachenecker 
et al2 
Bansal et 
al69 
Singh et 
al 68 
Asahina et al 
3
 
Present study 
Number of patients 
 
Age(Mean) 
 
Spectrum of 
patients 
 Incidence  of 
Autonomic 
dysfunction 
Duration of Illness 
at Presentation 
(Mean) 
 
Functional grade at 
presentation(Mean) 
Mechanical 
ventilation 
Mortality 
 
-Bladder 
dysfunction 
 
-Bowel dysfunction 
 
- Sweating 
abnormalities 
 
Tachycardia 
 
Bradycardia 
Fluctuation of HR 
Hypertension 
Hypotension 
Fluctuation of BP 
E-I differences 
7 
 
43+9 ys 
 
AIDP 
85.7% 
 
  26 day 
 
3.4 
 
Nil 
Nil 
 
- 
 
- 
 
6/7(85.71%) 
2/7(28.57%) 
0 
0 
4/7(57.14%) 
0 
1/7(14.29%) 
- 
13 
 
52.5 ys 
(29-70 ys) 
AIDP 
69%* 
 
<14 days 
 
3.5 
 
 23.08% 
Nil 
 
- 
 
- 
 
 
 
- 
 
- 
 
- 
- 
- 
+ 
+ 
+ 
15 
 
28.9 +9.9ys 
 
AIDP 
67.7% 
 
? 
 
? 
 
20% 
13.33% 
 
0 
0 
 
26.67% 
46.67% 
 
0 
 
- 
33.33% 
0 
- 
- 
24 
 
12-65 ys 
 
AIDP 
66.7% 
 
? 
 
? 
 
Nil 
8.33% 
 
20.8% 
0 
 
12.5% 
33.3% 
8.3% 
- 
20.8% 
- 
- 
30% 
15 
 
37.1+16.2ys 
 
13AIDP 
1AMAN 
 
 
6.5+3.7days 
 
3.4+0.9 
 
1/15 
Nil 
 
1/15 
0 
 
3AIDP 
1AMAN 
28.57%AIDP 
- 
-- 
- 
- 
- 
- 
8 
 
35.37+15.2ys 
 
7AIDP 
1AMAN 
87.5% 
 
3.75+2.05days 
 
3.75 
 
25% 
Nil 
 
12.5% 
50% 
 
37.5% AIDP 
75% 
37.5% 
75% 
75% 
50% 
75% 
3/6 (50%) 
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30:15 ratio 
Valsalva ratio 
Cold immersion test 
 
Tilt table/PCBP 
CV R-R 
SSR 
SSwR 
 
EEG changes 
Plasma 
Noradrenalin 
Pharmacological 
test 
Baroreceptor HR 
  reflex test using 
phenylephrin  
 
HR response to 
atropine 
- 
- 
2/3(66.77%) 
 
3/7(42.86%) 
- 
- 
- 
 
- 
- 
 
 
 
+(57.14%) 
 
- 
+ 
+ 
- 
 
- 
- 
- 
- 
 
- 
- 
 
 
 
 
 
- 
 
 
 
- 
- 
4/9(44.44%) 
40% 
 
20% 
- 
- 
- 
 
- 
- 
 
 
 
- 
 
+ (46.67% 
 
35% 
28.6% 
36.6% 
 
35% 
- 
- 
- 
 
33.33% 
- 
 
 
 
- 
 
- 
 
- 
- 
- 
 
0 
1(AIDP) 
- 
Absent in 
3AIDP 
2AMAN 
 
- 
Increased 
3AIDP 
1AMAN 
 
 
 
- 
 
- 
2/4(50%) 
1/2(50%) 
5/8(62.5%) 
 
½(50%) 
- 
4 
AIDP/1AMAN 
(62.5%) 
 
- 
 
 
 
25% 
 
- 
 
 
 
 
 
 
 
- 
 
 
 
- 
 
 
 (- =Not done/not mentioned, + Abnormal ,CV R-R=Coefficient of variation of R-R intervals,      
SSwR=sympathetic sweat response ,PCBP=Postural change of BP) 
  * >90 % subclinical sign of autonomic  dysfunction 
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Table 25 Showing relations of autonomic dysfunction  
Abnormalities P value 
Hyper acute onset of 
illness 
0.375 
High Hughes 
functional grade (4/5) 
1.00 
Older age(>45) 1.00 
Mechanical 
ventilation used 
1.00 
Sensory abnormality 0.250 
Cranial nerve abn. 1.00 
SSR abn. 0.375 
Table 27 Showing relations of  severe autonomic dysfunction 
Abnormalities P value 
Hyper acute onset 1.00 
High Huges 
functional garde(4/5) 
1.00 
Older age(>45) 0.035 
Mechanical 
ventilation  used 
1.00 
Sensory abnormalities 1.00 
Cranial nerve abn. 0.46 
SSR abnormalities 0.46 
Bradycardia 0.107 
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DISCUSSION 
A total of eight  patients underwent  a longitudinally performed autonomic function tests 
(ATs). 7/8 patients’ had AIDP and one patient had AMAN .They  were closely observed for  
the symptoms and sign of autonomic dysfunction including  continuous recording of HR and 
BP, cardiovascular response to autonomic function test and SSR to look for sudomotor 
function. The possibilities of hypoxemia,sepsis,pulmonary embolism,medication and 
electrolyte disturbances causing abnormalities were excluded before recording cardiovascular 
abnormalities in all these patients’ during the study period. The incidence of autonomic 
dysfunction in GBS has been reported to vary considerably earlier1,2,3,68,69. The variable 
incidence may be due to  differences in various techniques, extent of testing  and the arms of 
autonomic nervous system studied. Most of the available studies on autonomic dysfunction in 
GBS were done in limited number of patients, mainly  AIDP.Prospective  study  of  Singh et 
al69showed evidence of autonomic  dysfunction   in   16/24 GBS  patients (67.7%) and was 
similar to Bansal etal 69(66%) patients.Both  studies were done on AIDP patients’, but tested 
limited arms’ of autonomic nervous systems once and functional grades’,duration of illness 
and stages of the patients’ at the time of  study were not highlighted .Tuck andMcLeod study 
showed autonomic dysfunction in six of 7 AIDP studied.7 Tuck et al did not include 
symptoms of autonomic dysfunction and included patients’ even during the  plateau stages of 
disease .The mean duration of illness in Tuck’s study group was 26 days (7-63 
days).Flachenecker et al  studied cardiovascular functions in GBS quantitively and showed 
69 % of clinical and more than 90 % of subclinical sign of autonomic dysfunction  in 13 of 
AIDP2 .Flachenecker et al tested   autononomic function longitudinally upto I year of illness, 
but most of the patients included in this study were in the plateau stages’ but had  moderate to 
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severe grades’ of disease..Lichtenfds59 who  reported  12 prospective and16 retrospective  
cases of  GBS, which  showed  more than 60% to have cardiovascular abnormalities.In the 
present study , the evidence of autonomic dysfunction occurred  in  6/7patients with AIDP 
and one patient with AMAN (87.5%). The higher incidence of dysautonomia in our 
patients’could be due to the predominantly AIDP subtype, longitudinal study starting as early 
as the first two days and longitudinal studies including, continuous recording of HR and BP, 
multiple cardiovascular autonomic function test in each patient upto 4th weeks of illness  .The  
mean Hughes disability score and duration of illness at the time of presentation was 3.75 and 
3.75+ 2.05 days respectively. The study was designed to include autonomic symptoms and  
quantitative measures of autonomic dysfunction and tried to devise a Normalized Total 
Autonomic Score with the intention to classify the degree of Autonomic dysfunction- severe, 
moderate and mild grades.  The intention was to compare the type, spectrum and severity of 
autonomic dysfunction in the different stages of disease, week of illness and wanted to 
correlate the severity of dysfunction with the functional grade of disease and outcome, which 
has not been done earlier..Flachenecker et al2  studied   longitudinally  cardiovascular 
autonomic function test  upto 1 year of illness in 13 GBS and established 1st time Composite 
autonomic score to classify degree of autonomic dysfunction in different stages of illness.  
.Flachenecker did not include symptoms of autonomic dysfunction ,clinical cardiovascular 
manifestation of dysautonomia and SSR abnormalities in his scoring system. Flachenecker et 
al maximum composite score was 10 and composite score of  >7 was considered as sevre 
autonomic failure..Twenty five percent of our patients had NTAS >16,which was arbitrarily 
chosen to be having  severe autonomic dysfunction. Symptoms of dysautonomia  were 
reported in 6/8 (75%)patients and the autonomic symptoms had  started  1-5 days before the 
onset  of motor weakness in three patients. Postural dizziness was reported in two 
patients’(25 %), in one patient postural dizziness  preceded the onset of motor weakness by 5 
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days and this and persisted upto 10 weeks after the onset of neuropathy, inspite of improving 
motor weakness.The incidence of postural dizziness was comparable to the study by Singh 
(20.8%)68The bowel dysfunction was observed in 4/8 patients, 3 had evidence of 
constipation, where as one had both constipation and urinary retention.One patient had 
history of constipation 3 days preceding the motor weakness where as in another patient, 
urinary hesitancy  started  a  day prior to the onset of motor weakness.The  occurrence of 
constipation in  our study group  ( 50% ), was higher than 14 %  seen in the  MGH series, 
where-as  incidence of urinary retention (12.5 %)  was comparable to the study by Ravn22 
14/127 (11%) patients’, but less than 30 % of Litchtnfelds series and 27%  of MGH 
series59.Anhidrosis,the direct evidence of  impaired  sympathetic output  was observed in 
three patient (37.5%)  which was less than Tuck and McLeod series7 who reported anhidrosis 
in 6/7 of AIDP patients’ studied . Only one patient had palpitation, which was much less than 
29.17% reported by the study by Singh .68 
The most frequent manifestation of autonomic dysfunction seen in our patients’ was sinus 
tachycardia, which was similar to earlier reports.2,7,68,69and  is believed to be  due to 
sympathetic hyperactivity and/or parasympathetic underactivity. The sinus tachycardia  was  
observed 6/ 8 patients’ (75%) with GBS, which included   one patient with AMAN  in. The 
incidence of sinus tachycardia in  this study which was less than that reported by Tuck and 
Macleod (100%),but was  higher  than 46% reported by  Bansal   and 37% of the MGH 
series.In 37.5% patients’, a transient form of  bradycardia  was  observed  in this study, which 
was  comparable to the study by Singh (33%), and is believed to be due to Parasympathetic 
overactivity  or  afferent baro receptor failure.In the present study, the bradycardia was 
episodic, spontaneous and usually preceded by highly labile BP and HR.None of our patient 
required atropine or needed trans-venous pacing of the heart,. as reported earlier  in 7-34 % of 
patients 64,65. Systemic hypertension, a sign of sympathetic overactivity or baroreceptor 
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failure was detected in 6/8 (75%) patients’and was  persistent in 5 patients’ and paroxysmal 
in one patient. The occurrence of hypertension in our patients was  higher than  60% of 
Litchtnfelds series59 and  27 % of Tuck and Macleod series.7Paroxysmal hypertension(3%)  
in  Trux series 62 was   correlated with  quadriplegia and ventilatory  dependence,which was 
not  seen in our patients’.The maximum systolic and diastolic BP recorded in our patient was 
200 mm Hg  and 152 mmHg respectively .Hypertension and tachycardia were  not treated 
pharmacologically, except in one patient as most episodes of severe hypertension were 
transient , and none had developed hypertensive crisis as reported earlier7,56and treatment was 
withheld due to the risk of incipient hypotension and bradycardia by beta blocker and 
antihypertensive  agents’. One patient with persistent Hypertension  was treated with low 
dose of Atenolol and there were no inadvertent side effects.Episodes of hypotension was 
detected  in 4/8 patients’ (50%)only during PE and was  postural in one patient, where as in 
other three patients, this occured both spontaneously and during PE.The dysregulation of the 
parasympathetic and sympathetic systems’ is responsible for alterations in vasomotor tone 
and peripheral vascular resistance, most often causing transient or in some cases persistent 
hypotension. The minimum BP recorded in our patient was 54/40 mm of 
Hg(systolic/diastolic BP) and all episodes of  hypotension was treated with IV fluid 
challenge, and none of them required inotropic support’s/8  patients’ started having episodes 
of hypotension in this study, which  was  comparable to   42.8% of Tuck and Macleod 
series,7but was much less than  75% seen in the series of Pfeiffer et al.64 Labile BP and HR 
was also very common form of  clinical sign of autonomic dysfunction in this study  and was 
observed in 75 % of the patients’ at different points’ of time, during the study period .Labile 
BP can be attributed to disturbances in the baroreceptor reflex pathway as well as changes in 
the catecholamine levels. 83 Labile  HR(>30bpm), Labile BP(>40mmHg systolic BP) and 
bradycardia was reported as a predictor of significant arrhythmias, including  risk factor for 
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asystole  in a study by Winer .84.Significant fluctuation of  HR and BP, mainly  episodes of 
tachycardia and   hypotension was observed  in 50%  cases during plasma exchanges  and 
was managed with frequent termination of procedure and IV fluid challenge. In one patient 
(pt number 3), there were  frequent episodes of  hypotension (upto 60/44 mm Hg ) during 
PE,so, PE  was  discontinued and IV Ig  was started, which she tolerated and had good 
outcome. In  our patients’, the number of  of studies using  non-invasive cardiovascular  
autonomic function  tests  were  small due to the presence of motor deficits,  facial   and 
bulbar paresis, or use of mechanical ventilation  mainly  during the  time  of maximal 
weakness. HR response to deep breathing (I-E differences) was abnormal in 3/6 (50%) 
patients’, whereas HR response to active standing (30:15 ratio)was  abnormal in  1/2 
patients’, who were  able to perform the  test . Out of the two patients who were  able to 
perform  valsalva  maneuver ,one  had shown abnormal valsalva  ratio(50%). 62.5% of  
patients’ failed  to have a rise of diastolic BP significantly in Cold immersion test,  where as 
50 % of the  patients’,  who were  able to stand unsupported,  was showing significant fall of 
systolic BP on standing at or before 3 min.(>30mmHg).SSR was done in all eight patients, of 
which five had absent response (62.5%) (4 AIDP/ 1 AMAN) in both upper and lower 
limbs.All patients with absent SSR had evidence of dysautonomia. Three patients’, in whom  
SSR was present, 2 had a mild degree of dysautonomia and the third patient did not develop   
autonomic dysfunction during the study period of three weeks’. The SSR abnormalities of our 
patients(5/8) was higher than 5/ 13 as reported by Taly et al,76 but less than  12/12 in the 
series of Deniz Yerdelen.77.SSR abnormalities in our patients did  not correlate with the 
presence or severity of autonomic dysfunction significantly  as reported by the earlier two 
studies76,,77The most common ECG pattern  was sinus tachycardia as reported in earlier 
studies,  but in  one   patient  ECG  showed T wave inversion in inferior and lateral leads, 
associated with ST  segment depression in lateral leads, where as another  patient  showed  T 
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wave inversion in anterior and lateral leads.Echocardiography and cardiac enzymes were 
found to be normal, and on further evaluation of both these patients with ST-T changes, this 
was considered probably related to activation of sympathetic nervous system leading to 
catecholamine associated mild myocardial injury.None of our our patients’showed any   life 
threatening cardiac arrhythmias, unlike other published studies 85,86,probably  this could be 
due to small number of patients’ in our study.The normalized total  autonomic score was  
maximum  during progressive stage of the illness and  subsequently started normalizing in the 
plateau phase. This was  in  accordance  with  the  observation  that  clinically overt  signs  of  
autonomic  dysfunction were mainly encountered  during the early stages of the  disease.2,68,69 
Resting tachycardia,bradycardia, episodes of hypertension and spontaneous hypotension  
started improving earlier than  significant diurnal variation of HR and BP and bed side 
cardiovascular autonomic function tests’.Two of our patients were showing persistence  of  
autonomic dysfunction inspite of improvement in the  Hughes functional grade at 4th week of 
illness ,dysautonomia improved in one patient with   persistence of  ventilatory dependency at 
the termination of study(end of 4 weeks),  where as in remaining five patients, dysautonomia  
was started normalizing  with improving  motor deficits. The degree of dysautonomia in our 
patients was variable and involving both sympathetic and parasympathetic components’ of 
autonomic nervous system with considerable overlap. The evidence of sympathetic and/or 
parasympathetic over and /or under activity was present even in same patient at the same time 
or different points’ of time, which was reported in an earlier studies. 
It was difficult to locate the exact site of lesion in the present study. Two of our patients’ had 
evidence of predominantly sympathetic dysfunction,one  predominantly parasympathetic 
dysfunction where- as, the other four had evidence of both sympathetic and parasympathetic 
dysfunction of variable severity at  different points in  time.One patient( pt number 2 ) was 
showing significant postural dizziness, which was started 5  days prior to onset of motor 
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weakness and persisted upto 10 weeks even after significant improvement of  Hughes 
functional grade, and she had postural fall of systolic BP >30 mm Hg and failure to rise of 
normal diastolic pressure in cold immersion test till the termination of study at the end of 3rd 
weeks   with normal rise of HR during deep breathing and standing ,normal HR response in 
Valsalva test and absence of episodes of hypertension ,tachyacardia bradycardia or labile BP 
and HR  during the entire study period and suggested probable involvement of efferent 
sympathetic fibers  predominantly with intact baro receptor functions .But,the  SSR was 
normal.One patient was showing  persistent sinus  tachycardia ,abnormal rise of diastolic BP 
in cold immersion test, significant postural fall of systolic BP, normal rise of HR following 
deep breathing and standing and suggested combined involvement of afferent baroreceptor 
and Sympathetic efferent with absence  of SSR in both upper and lower limbs and significant 
bulbar dysfunction.One of our patient was showing significant hypertension and sinus 
tachycardia, labile  HR and BP ,upto 4th weeks of illness ,failure to rise of HR on deep 
breathing and standing with presence of  SSR in both upper and lower limbs and suggested 
abnormal baroreceptor function .This patient was not showing clinically evident bulbar 
dysfunction.Our patient who had the maximum normalized autonomic score  (NTAS) 19.2 
was showing maximum fluctuation of systolic BP over 24 hrs(mean daily fluctuation of  
systolic BP 81.66 mmHg), intolerance to PE and ST changes suggestive of myocardial injury. 
Labile systolic BP (>40 mmHg/day) was the most important predictor of life threatening 
arrhythmias in an earlier study.83 The NTAS was not showing any correlation with symptoms 
of orthostatic intolerance, as patient who was having significant postural dizziness was 
grouped in the  mild autonomic failure category in present study with maximum NTAS 8.35 
during the progressive stage of disease.  The only patient who had AMAN, was found to have 
a moderate degree  of dysautonomia, including sympathetic,Parasympathetic,Sudomotor  and 
bowel  dysfunction  which started normalizing  by the 2nd week and improved by the end of 
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3rd weeks with non improving motor disability. The pattern of involvement of autonomic 
nervous system in AMAN of our study was different from  Asahina’s series of patients, who 
studied 8  AMAN and compared them with 7 AIDP cases3.According to Asahina’s study, 
AIDP have mainly cardiovascular sympathetic hyperactivity with sudomotor hyper or 
hypofunction but AMAN had  mainly sudomotor hypofunction with preserved cardiovascular 
function.This differences probably may be due to the fact that Asahina’s patients’ had milder 
grade of disease. There was  one patient in this study in whom dysautonomia was not 
observed, and this patient had AIDP, with a  hyper acute  onset of illness , presence  of 
bifacial and bulbar involvement  with Hughes functional grade of 4 at the peak of illness .The 
present study was not showing  any  significant correlation  between presence  or severity  of  
dysautonomia(NTAS) with  grade of motor  weakness (p=0.537) or sensory 
disturbances(p=0.64), although most studies showed correlation 2,62, but a few other studies 
had shown no correlation 59,68,69. In contrast to other studies2 our  study was  not showing  
correlation of  severity of  dysautonomia with  respiratory compromise requiring mechanical 
ventilation .The severity of dysautonomia was showing positive correlation with  older age of 
onset  of illness, which was statistically significant.(P=0.03) 
 
 
Limitations of study 
 
1) Small sample size.  
2) All  cardiovascular autonomic function test  were not be  performed in every  patient mainly 
at the peak of motor weakness 
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CONCLUSIONS 
1) The present study demonstrated high incidence of autonomic dysfunction in patient  
    With GBS (87.5%).      
  2) Autonomic dysfunction was detected in 6/7 patients’ with and one patient with   AMAN.   
Fifty percent patients had evidence of both sympathetic and parasympathetic dysfunction, 
25%had predominantly sympathetic dysfunction,where as 12.5% patients had   
predominantly parasympathetic dysfunction 
3) The degree of dysautonomia (NTAS) was maximum  during the first 2 weeks of illness in      
majority of patients’ and started normalizing thereafter. 
4) Severe Dysautonomia was  seen  in 25 % patients’, moderate degree of dysautonoma in 
37.5 % patients,mild degree  in 25 % patients 
5) The severity of dysautonomia correlated with older age (>45 yrs) of onset of illness, which 
was statistically significant  
6) The presence and severity of dysautonomia(NTAS) did not show correlation with motor   
disability,sensory disturbances and use of mechanical ventilation 
7) The autonomic dysfunction was not fatal in this study 
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Appendix 1  
DATA COLLECTION PROFORMA 
             
 
History                                                                 Date of diagnosis :: 
 
History   Days since onset of symptoms::     1 week  (       )              2   weeks   (        ) 
                                                                        3 weeks(        )             4  weeks    (        ) 
 
Preceding history    :-   Diarrhoea   (         )      URI    (       )    Vaccination   (         ) 
 
 
    Code –             diarrhoea –yes – 1 ,          URI – yes -2 ,    Vaccinat – yes – 3  
 
 
Co-morbidities : 
Hypertension   Y / N   Smoking   Y / N   
Diabetes mellitus Y  / N                                   
     
 
Chronic diarhea          Y/ N                                Renal failure     Y / N                 
   
 
 
Name: 
 
Hospital Number: 
 
Dob:  Age: 
Address: 
 
Telephone/E-mail: 
 
Seen by: 
76 
 
Coding for  Symptoms 
 
Sensory  
Parasthesia  
        1 
.Symptoms 
limited to 
fingers or toes 
 
 
       2  
.Symptoms 
extend to ankle 
or wrist 
    3.  
Symptoms 
extend to knee 
or elbow 
     4.  
Symptoms 
above knees or 
elbows, or 
functionally 
disabling 
5 
Facial 
involvement 
6 
Trunkal 
involvement 
Sensory loss          1 
Symptoms 
limited to 
fingers or toes 
        2 
Symptoms extend to 
ankle or wrist 
    3 
Symptoms extend 
to knee or elbow 
       4 
Symptoms above 
knees or elbows, 
or functionally 
disabling 
5 
Facial 
involvement 
6 
Trunkal 
involvement 
pain          1 
.Symptoms 
limited to fingers 
or toes 
 
 
       2  
.Symptoms 
extend to ankle or 
wrist 
    3.  
Symptoms extend 
to knee or elbow 
     4.  
Symptoms above 
knees or elbows, 
or functionally 
disabling 
5 
Facial 
involvement 
6 
Trunkal 
involvement 
Type of pain        1  Burning type       2  Pricking type     
Motor         1 
Difficulty in hand 
grip  
        2 
Difficulty in 
combing, reaching 
up to shelf 
        3 
Difficulty in 
turning in bed  
   4  
Bulbar symptoms  
  
        5   Difficulty in 
gripping foot 
wear, footwear 
slipping off with 
knowledge 
     6 
Twisting of 
ankle, buckling 
of knee  
      7 
Difficulty in 
getting up from 
squat  
     8 
Complete 
paralysis 
  
Cranial nerve involvement     
Cranial nerve Day 1 Day 2 Day 3 Day 7 2nd week 3rd week 4th weeks 
Fundus        
Pupil        
Eye 
movement 
       
Trigeminal        
Facial        
Vest cochlear        
Palate        
Sternomastoid        
Tongue        
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Motor  Examinations  
                       Bulk and Tone                                 
 week 1 week 2 week 3 week 4 
Wasting      
Tone      
                                                                                                          0 = normal,  1 = decreased , 3 increased         
Power                                                                                     
 week 1 week 2 weeek 3 week4 
Power  R L R L R L R L 
Neck flx         
Neck ext         
Trunk          
Should Ab         
Should Add          
Elbow Flx         
Elbow Ext          
Wrist Flx          
Wrist Ext          
Hip Flx          
Hip Ext          
Knee Flex          
Knee Ext          
Dorsiflx          
Plantar         
                                                                                                            MRC Grading                
                                                                                                                                              0  No movement                                                                                                                          
                                                                                            1  Flicker 
                            2  Movement not against gravity 
                                                                                                                       3 Movement against gravity 
                                                                                                          4  Against gravity                                                                                           
l                                                                                             5 Normal    
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Reflex Grading 
 0 Absent 
 +/-  Present with reinforcement 
+ Decreased 
 ++ Normal 
 +++ Increased 
 C With clonus 
 
Symptoms of dysautonomia 
 
Clinical cardiovascular function 
 
 week 1 week 2 week 3 week 4 
Reflexes  R L R L R L R L 
Biceps          
Brachiorad          
Triceps          
Knee          
Ankle          
Sup abd         
plantar         
Day 1 Day 2 Day 3 Day 7 2nd week 3rd week 4th weeks 
 
 
      
Day 1 Day 2 Day 3 Day 7 2nd week 3rd week 4th weeks 
Resting HR       
Fluctuation of 
HR 
      
Systolic BP       
Diastolic BP       
Fluctuation of 
SBP 
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Clinical autonomic  function test 
 
Bladdar dysfunction 
 
Day 1 Day 2 Day 3 Day 7 2nd week 3rd week 4th weeks 
I-E differences       
30:15 ratio       
Valsalva ratio       
Postural fall of 
SBP 
      
Cold 
immersion test 
      
Bowel 
dysfunction  
Day 1 Day 2 Day 3 Day 7 2nd week 3rd week 4th weeks 
Nil         
Bloating         
Sluggish bowel 
sound  
       
Constipation         
Hyperactive 
bowel sound 
       
Bladdar 
dysfunction  
Day 1 Day 2 Day 3 Day 7 2nd week 3rd week 4th weeks 
Nil         
Frequency         
Urgency          
Hesitancy          
Retention         
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Sweating abnormality 
 
 
   a-localised to feet/LL 
    b-localised to hand /UL 
    c-localised to trunk 
     d-localised to face 
     e -Generalised  
Electrophysiology  
 week1 week2 week3  week4  
NCV      
EMG      
SSR     
                                                                                                               0 = normal, 1 = abnormal        
Type of Neuropathy :  AIDP /AMSAN/ AMAN /MF 
 
 
Sweating 
abnormality  
Day 1 Day 2 Day 3 Day 7 2nd week 3rd week 4th weeks 
Nil         
Cold to touch        
Hot to touch         
Anhidrosis         
Hyperhidrosis         
Episodic 
flushing  
       
Episodic 
sweating  
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CSF – TC                                                     ECG Changes 
            DC 
            SUGAR 
            PROTEIN 
   Treatment  received  
  
 Plasmapheresis  Days  of illness         amount           remark     
                           
IV Ig             
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Appendix 2    Informed Consent 
PATIENT’S INFORMATION 
 I understand that department of Neurological sciences is doing a study to:  
1.To  study autonomic nervous system involvement in patient with  Guillain- Barré  
   Syndrome (GBS)  
2.To  assess the clinical significance of the autonomic nervous system involvement in such 
patients 
3.To  assess  the relation  of autonomic dysfunction  with clinical severity of GBS . 
 
The study involves collection of patient information, clinical data and test reports done as 
part of regular clinical care.  I also understand that some of the tests done in connection with 
the study may directly benefit me whereas the other tests are likely to benefit other patients 
with the disease. 
I understand that my withdrawal from the study, at any time will not affect the treatment 
being given. 
Study Title: Study of autonomic dysfunction in patients  with Guillain-Barré Syndrome 
(GBS) 
Study Number: 
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______ 
Please initial box  
(Subject) 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [    ] 
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(ii) I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected. [    ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission  
to look at my health records both in respect of the current study and any further research that 
may be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any information released to 
third parties or published. [    ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [    ] 
(v) I agree to take part in the above study. [     ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
 
 
84 
 
Appendix 3 Master chart 
Chart showing clinical characteristics of patients 
Patient Number  1 2 3 4 5 6 7 8 
Age(yrs) 19 22 47 60 44 19 30 43 
Sex M F F F M M M M 
Spectrum of GBS AIDP AIDP AIDP AIDP AMAN AIDP AIDP AIDP 
Days of illness at 
presentation 
2 2 4 2 3 4 8 5 
DS at admission 5 2 4 4 4 4 3 4 
DS at 
discharge/termination 
of study 
3 2 3 3 5 3 3 3 
Onset to nadir (days) 12 10 12 2 7 1 20 11 
Antecedent events Nil Myalgia & 
arthralgia 
Myalgia & 
arthralgia 
Nil Diarrhoea Diarrhoea Nil URTI 
Cranial nerve 
involvement 
Bifacial& 
bulbar  
Nil 
 
Nil 
 
Bifacial Bifacial & 
Bulbar 
Bifacial & 
Bulbar 
Bifacial Bifacial& 
Bulbar 
Sensory 
symptoms/sign 
Nil Yes Yes Yes Yes Nil Yes Yes 
Bladder dysfunction Nil Nil Nil Yes Nil Nil Nil Nil 
Bowel dysfunction Nil Nil Nil Yes Yes Nil Nil Yes 
Sweating 
abnormalities 
1 Nil Yes Yes Nil Nil Nil Nil 
SSR Abnormalities Yes Nil Yes Yes Yes Nil Nil YES 
ECG changes Nil Nil Yes Yes Nil Nil Nil Nil 
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Chart showing  clinical cardiovascular function  upto 4th week of illness 
        
Patients Number 1 2 3 4 5 6 7 8 
Resting 
HR 
(bpm) 
Day 1 122 
 
78 110 104 114 92 NA 116 
Day2 130 
 
104 114 114 110 100 118 112 
Day3 
 
116 110 122 120 112 98 120 112 
Week2 114 90 
 
130 116 98 78 114 136 
Week3 110 74 
 
96 106 102 82 108 92 
Week4 
 
86 NA 92 NA 76 NA 110 NA 
Daily 
Fluctuation 
of HR 
(Mean) 
Day 1 80 20 68 52 56 24 NA 50 
Day2 90 30 62 49 62 30 36 56 
Day3 
 
65 28 57 60 50 22 46 48 
Week2 65 24 54 62 40 18 70 80 
Week3 54 20 40 38 44 14 24 34 
Week4 
 
60 NA 18 NA 22 NA 29 NA 
Systolic  
 BP 
(mm of Hg) 
Day 1 150 90 188 176 168 126 NA 156 
Day2 152 100 152 160 170 118 162 160 
Day3 
 
148 104 154 130 158 120 160 166 
Week2 164 108 152 134 152 118 146 132 
Week3 166 102 160 128 120 110 148 110 
Week4 
 
122 NA 140 NA 130 NA 134 NA 
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Chart showing clinical cardiovascular function  upto 4th week of illness 
            
Patients Number 1 2 3 4 5 6 7 8 
Diastolic BP 
(mm of Hg) 
 
Day 1 92 
 
50 114 104 134 70 NA 108 
Day2 86 
 
62 100 94 98 78 134 102 
Day3 
 
94 
 
60 110 74 80 88 98 92 
Week2 96 
 
70 136 80 100 74 90 86 
Week3  
80 
78 88 78 68 70 92 72 
Week4 
 
70 NA 72 NA 72 NA 94 NA 
Daily  
Fluctuation  
of Systolic    
  BP 
( Mean) 
 
 
Day 1 78 20 146 80 86 22 NA 50 
Day2 7 22 70 30 100 30 101 64 
Day3 
 
52 22 78 38 84 34 64 58 
Week2 72 26 49 32 60 18 58 50 
Week3 70 14 78 36 22 34 50 20 
Week4 
 
38 NA 60 NA 24 NA 20 NA 
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Chart showing  cardiovascular autonomic function test  upto 4th week of 
illness          
Patients Number 1 2 3 4 5 6 7 8 
30:15 ratio Day 1 ND 1.02 ND ND ND ND ND ND 
Day2 ND 1.6 ND ND ND ND ND ND 
Day3 
 
ND 2 ND ND ND ND ND ND 
Week2 ND 1.03 ND ND ND 1.8 0.09 ND 
Week3 ND 1.08 ND ND ND 1.06 0.08 1.08 
Week4 
 
ND NA ND NA ND NA 1.03 NA 
I-E 
differences 
Day 1 ND 18 8 10 ND 18 NA ND 
Day2 ND 20 10 12 ND 16 NA ND 
Day3 
 
ND 18 8 16 ND 19 NA ND 
Week2 ND 19 12 12 ND 18 12 20 
Week3 ND 16 10 10 ND 20 10 18 
Week4 
 
ND NA 10 NA ND NA 10 NA 
Valsalva 
ratio 
Day 1 ND 1.42 0.8 ND ND ND NA ND 
Day2 ND 1.64 0.6 ND ND ND ND ND 
Day3 
 
ND 1.44 0.9 ND ND ND ND ND 
Week2 ND 1.82 1.01 ND ND ND ND ND 
Week3 ND 1.76 1.14 ND ND ND ND ND 
Week 4 ND NA 1.18 NA ND NA ND NA 
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Chart  showing   cardiovascular autonomic function test  upto 4th week of 
illness 
 
Patients Number 1 2 3 4 5 6 7 8 
 
 
Fall of SBP 
on 
standing 
upto 3 
min. 
(mm of 
Hg) 
 
 
Day 1 ND 34 ND ND ND 8 NA ND 
Day2 ND 38 ND ND ND 6 ND ND 
Day3 
 
ND 40 ND ND ND 10 ND ND 
Week2 ND 34 ND ND ND 8 ND ND 
Week3 ND 36 ND ND ND 4 +6 14 
Week4 
 
ND NA ND NA  ND NA -8 NA 
Cold 
immersion 
test 
( mmHg ) 
 
 
 
 
 
 
Day 1 8 6 2 12 16 18 NA 20 
Day2 10 4 8 13 18 16 NA 22 
Day3 
 
14 8 6 16 18 20 NA 18 
Week2 6 6 2 13 20 16 16 14 
Week3 12 8 2 12 16 18 18 12 
Week4 
 
18 NA 12 NA 22 NA 16 NA 
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